Neoadjuvant-Adjuvant Pembrolizumab Therapy Increases Survival in Advanced Skin Cancer

The Oncology Brothers are joined by Dr. Sapna Patel, Director of Unveal Melanoma, Program Director of Melanoma Fellowship, and Associate Professor at the University of Texas – MD Anderson Cancer Center, to discuss melanoma highlights from ESMO 2022. Among the studies discussed, the group detailed a newly published study which showed that pembrolizumab administered both before and after surgery increases event-free survival in patients with resectable stage III/IV melanoma compared with pembrolizumab given after surgery alone.